Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis.

Defective control of Epstein-Barr virus (EBV) infection by cytotoxic CD8+
T cells might predispose to multiple sclerosis (MS) by allowing
EBV-infected autoreactive B cells to accumulate in the central nervous
system. We have treated a patient with secondary progressive MS with in
vitro-expanded autologous EBV-specific CD8+ T cells directed
against viral latent proteins. This adoptive immunotherapy had no
adverse effects and the patient showed clinical improvement with reduced
disease activity on magnetic resonance imaging and decreased
intrathecal immunoglobulin production. This is the first report of the
use of EBV-specific adoptive immunotherapy to treat MS or any other
autoimmune disease.

No comments: